Decitabine-Cedazuridine (Inqovi) for MDS - Details


( Last Updated : September 22, 2021)
Generic Name:
Decitabine-Cedazuridine
Project Status:
Active
Manufacturer:
Taiho Pharma Canada, Inc.
Brand Name:
Inqovi
Project Line:
Reimbursement Review
Project Number:
PC0228-000
Tumour Type:
Leukemia
NOC Date:

Details


Tumour Type:
Leukemia
Indications:
Myelodysplastic Syndromes (MDS)
Funding Request:
INQOVI (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.
Review Status:
Final Recommendation Posted
Date NOC Issued:
Sponsor:
Taiho Pharma Canada, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Funding Request:
INQOVI (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.
pERC Meeting:
Final Recommendation Issued: